Evercore Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $16
Evercore has reiterated its Buy rating for Novocure (NVCR.US) but has adjusted its target price downwards to $16. This revision in the target price suggests a moderated outlook on the stock's future performance despite maintaining a positive investment recommendation.
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer
NovoCure's stock jumped after its Phase 2 PANOVA-4 trial showed statistically significant improvement in disease control for first-line metastatic pancreatic cancer using Tumor Treating Fields (TTFields) therapy in combination with other treatments. This data highlights the potential of TTFields to expand its clinical use in aggressive cancers and strengthens Novocure's investment narrative, although challenges like adoption and reimbursement remain. The company's future revenue and earnings forecasts suggest a substantial upside to its current stock price.
JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR
JPMorgan Chase & Co. significantly increased its stake in NovoCure Limited by 104.2% in Q3, purchasing 144,024 shares to hold a total of 282,184 shares, valued at approximately $3.65 million. This contrasts with recent insider selling activity, as CEO Frank X. Leonard and COO Mukund Paravasthu sold a combined 140,041 shares. NovoCure recently surpassed EPS estimates with ($0.22) versus ($0.41) expected, and analysts currently maintain a consensus "Hold" rating with a target price of $26.93.
SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR
SG Americas Securities LLC significantly increased its stake in NovoCure Limited (NVCR) by 905.6% in the fourth quarter, now holding 278,806 shares valued at $3.605 million. This institutional buying contrasts with recent insider selling activities, as company insiders disposed of 140,041 shares totaling $1.86 million over the past three months. Despite a recent 2.7% drop in stock price, several brokerage firms have maintained "Buy" or "Hold" ratings for NovoCure, with an average target price of $26.93.
NovoCure (NVCR) Jumps After Strong PANOVA-4 Data Validates TTFields Combo Potential In Pancreatic Cancer
NovoCure's stock surged following positive Phase 2 PANOVA-4 trial results for its Tumor Treating Fields (TTFields) therapy in metastatic pancreatic cancer, showing significant improvement in disease control when combined with atezolizumab and gemcitabine/nab-paclitaxel. This data strengthens the scientific basis for TTFields in hard-to-treat cancers and builds on previous FDA approval for locally advanced pancreatic cancer. Investors are now focused on regulatory approval, commercial execution, and potential adoption of the therapy.
NovoCure Ltd to release first quarter 2026 financial results on April 30
NovoCure Ltd has announced that it will release its financial results for the first quarter of 2026 on April 30. Investors and analysts will be closely watching these results to assess the company's performance, especially in light of its recent positive Phase 2 trial results for its TTFields therapy in the PANOVA-4 study. The company continues to focus on innovative cancer treatments, and the upcoming financial report will provide context for its recent clinical progress.
Novocure will post Q1 results before market open on April 30
Novocure (NASDAQ: NVCR) is set to release its first-quarter 2026 financial results on April 30, 2026, before the U.S. financial markets open. The company will also host a conference call and webcast at 8:00 a.m. EDT on the same day to discuss these results. Novocure, an oncology company focusing on Tumor Treating Fields therapies, uses its investor relations website for disclosing material non-public information in compliance with Regulation FD.
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages
Seven brokerages have given NovoCure Limited (NASDAQ:NVCR) an average "Hold" rating, with a consensus 12-month price target of $26.93. Despite slightly beating quarterly EPS estimates and an 8.2% revenue increase, the company remains unprofitable, trading near its 1-year low. Recent insider selling also occurred, with the CEO and another insider selling shares in March.
A Look At NovoCure (NVCR) Valuation After Extended Share Price Weakness
NovoCure (NVCR) has experienced significant share price weakness recently, including a 41.83% decline over the past year. Despite this, a popular narrative suggests the company is 57.7% undervalued, with a fair value estimate of $25.93 against its current price of $10.97, due to potential regulatory approvals and market expansion for its TTFields therapy. However, this optimistic outlook depends on faster therapy adoption and broader reimbursement, while acknowledging risks associated with ongoing losses and reliance on a single technology.
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Maintains Target Price $49
H.C. Wainwright has reaffirmed its Buy rating for Novocure (NVCR.US) and maintained a target price of $49. This indicates a continued positive outlook on the company's stock performance from the analyst firm.
Vanguard disaggregates ownership reporting for Novocure (NVCR) after realignment
Vanguard has filed an amended Schedule 13G/A for Novocure (NVCR), reporting 0 shares beneficially owned and 0% of the class. This change is due to an internal realignment on January 12, 2026, where Vanguard will disaggregate the reporting of certain subsidiaries, relying on SEC Release No. 34-39538. This action clarifies that the filing reflects a change in reporting structure, not a sale of shares, and suggests that individual Vanguard-affiliated entities may file separate disclosures for any actual holdings.
NovoCure Tumor Treating Fields Shows Improved Outcomes In Tough Pancreatic Cancer
NovoCure's (NASDAQ: NVCR) Tumor Treating Fields (TTFields) therapy has shown promising results in the Phase 2 PANOVA-4 trial for metastatic pancreatic ductal adenocarcinoma, with a disease control rate of 74.4% and an objective response rate of 34.6%. The treatment was well-tolerated, offering a potential new option for this aggressive cancer. Despite positive clinical news and a recent FDA approval for Optune Pax in locally advanced pancreatic cancer, the stock currently shows some short-term technical weakness.
Does Positive PANOVA-4 Data Alter the Bull Case For NovoCure’s TTFields Platform (NVCR)?
Novocure recently announced positive Phase 2 PANOVA-4 trial results for its Tumor Treating Fields (TTFields) in metastatic pancreatic cancer, showing improved disease control. This data supports the broader application of TTFields beyond glioblastoma (GBM) and its integration with immunotherapies, potentially influencing Novocure's long-term investment narrative. However, ongoing challenges related to real-world adoption and reimbursement remain significant risks despite the promising clinical findings.
Does Positive PANOVA-4 Data Alter the Bull Case For NovoCure’s TTFields Platform (NVCR)?
NovoCure recently reported positive Phase 2 PANOVA-4 trial results for its TTFields platform in metastatic pancreatic cancer, showing improved disease control. This data supports the expansion of TTFields beyond GBM into other solid tumors, although slow real-world adoption and reimbursement challenges remain significant risks. Investors are watching to see if pancreatic and lung indications can diversify NovoCure's revenue and address ongoing unprofitability.
PANOVA-4 Phase 2 trial shows promising TTFields therapy results, NovoCure Ltd reveals
NovoCure Ltd has announced positive results from its Phase 2 PANOVA-4 trial, which evaluated its innovative Tumor Treating Fields (TTFields) therapy. This non-invasive treatment targets tumor growth, and the company shared further details in an official press release. This news follows recent Japanese government approval for insurance reimbursement of NovoCure's lung cancer treatment and the release of its financial results for Q4 and full year 2025.
Novocure (NASDAQ: NVCR) reports positive PANOVA-4 pancreatic cancer data
Novocure announced positive topline results from its Phase 2 PANOVA-4 trial for metastatic pancreatic ductal adenocarcinoma, showing Tumor Treating Fields (TTFields) therapy combined with atezolizumab, gemcitabine, and nab-paclitaxel significantly improved the disease control rate to 74.4%. This represents a 26.4% improvement over historical controls. The therapy was well-tolerated, with an objective response rate of 34.6% and median overall survival of 9.7 months, strengthening the case for TTFields in pancreatic cancer.
Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR
Tudor Investment Corp ET AL significantly increased its stake in NovoCure Limited by 140.6% in the third quarter, acquiring an additional 354,216 shares to hold a total of 606,070 shares. This move comes as institutional investors collectively own 84.61% of the stock, despite recent notable insider selling by company executives like COO Mukund Paravasthu and Chairman William F. Doyle. While NovoCure reported better-than-expected Q1 earnings, beating EPS estimates, the company remains unprofitable with negative margins.
NovoCure Limited $NVCR Position Lifted by Algert Global LLC
Algert Global LLC significantly increased its stake in NovoCure Limited by 372.2% in the third quarter, now owning 0.61% of the company's stock valued at $8.82 million. Other institutional investors also modified their holdings, bringing total institutional ownership to 84.61%. Despite recent insider selling, analysts have a consensus "Hold" rating on NovoCure with a target price of $26.93, following a quarter where the company exceeded EPS estimates but slightly missed revenue projections.
Capital World Investors Lowers Holdings in NovoCure Limited $NVCR
Capital World Investors significantly reduced its stake in NovoCure Limited (NASDAQ:NVCR) by 68.7% in the third quarter, selling over 4.3 million shares. Despite this, NovoCure has received mixed analyst ratings with an average "Hold" and a target price of $26.93, and reported an EPS beat and 8.2% YoY revenue growth in its latest quarterly results. Insiders have also sold shares totaling approximately $1.86 million in the last 90 days.
FDA Approves Novocure’s Optune Pax Wearable Device for Pancreatic Cancer
The FDA has approved Novocure's Optune Pax, a wearable device for adults with locally advanced pancreatic cancer, to be used alongside chemotherapy. This device utilizes tumor-treating fields (TTFields) to disrupt cancer cell division, showing an increase in overall survival and time to pain progression in clinical trials. Novocure's CEO stated that it represents a significant new biophysical treatment approach for a disease that has seen little therapeutic innovation in decades.
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?
NovoCure secured National Health Insurance reimbursement in Japan for Optune Lua, a treatment for advanced non-small cell lung cancer, which broadens access to its Tumor Treating Fields technology. This development could reshape investor perspectives on NovoCure's access, utilization, and growth story, potentially influencing its projected 2026 revenues and contributing to a higher fair value estimation by some analysts. Despite this positive news, investors are cautioned to consider the company's persistent net losses and dependence on a single technology platform.
Should Japan’s Optune Lua Reimbursement Win Reframe NovoCure’s (NVCR) Access and Utilization Story?
NovoCure secured National Health Insurance reimbursement in Japan for Optune Lua in treating advanced non-small cell lung cancer, a significant step for its Tumor Treating Fields technology. This approval is expected to influence NovoCure's investment narrative by potentially easing access barriers and supporting revenue growth, though the company continues to face challenges with net losses. The decision aligns with analysts' optimistic revenue models and could lead to increased investor confidence regarding the therapy's expansion and utilization.
NovoCure (NASDAQ: NVCR) ex-CEO uses 17,638 shares to cover RSU taxes
NovoCure Ltd's former CEO, Ashley Cordova, had 17,638 ordinary shares withheld on March 4, 2026, to cover tax obligations related to vesting Restricted Stock Units (RSUs). The shares were withheld by the issuer at $13.30 per share as a non-discretionary tax-withholding disposition. Following this transaction, Cordova directly owns 422,570 ordinary shares of NovoCure.
[Form 4] NovoCure Ltd Insider Trading Activity
NovoCure Ltd's Chief Operating Officer, Paravasthu Mukund, reported receiving 45,112 restricted share units and stock options for 7,518 and 58,488 Ordinary Shares on March 3, 2026, with vesting contingent on continued employment. Subsequently, Mukund sold 5,377 Ordinary Shares on March 4, 2026, at a weighted average price of $13.3054 and 43,246 Ordinary Shares on March 5, 2026, at $13.7740. These sales were "sell to cover" transactions to meet tax withholding obligations, not discretionary trades.
NovoCure (NASDAQ:NVCR) Trading Down 7.7% Following Insider Selling
NovoCure (NASDAQ:NVCR) shares fell 7.7% after significant insider selling, with Chairman William F. Doyle selling 71,887 shares and COO Mukund Paravasthu selling multiple tranches. Despite this, the company reported an EPS beat and 8.2% year-over-year revenue growth. Analysts have mixed ratings, ranging from "Buy" to "Sell," with a consensus "Hold" rating and an average target price well above the current valuation.
NovoCure (NVCR) CEO gets major equity grants and sells shares for taxes
NovoCure Ltd. CEO Leonard Frank X received significant equity grants, including 150,000 restricted share units and 216,388 stock options, both vesting over several years contingent on continued employment. He also sold 5,607 ordinary shares at a weighted average price of $13.3054 to cover tax withholding obligations associated with restricted stock unit vesting, a mandated "sell to cover" transaction. Following these transactions, the CEO directly holds 493,793 ordinary shares and 216,388 stock options.
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua
Novocure (NVCR) gained reimbursement approval in Japan for its Optune Lua device, opening access to a large, insurance-backed market for non-small cell lung cancer patients. Despite recent positive share price movements, longer-term returns are significantly down. The article explores whether the fair value estimate of $25.21, significantly higher than the current $13.42, indicates future upside or if the market has already factored in growth expectations.
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua
Novocure (NVCR) has received reimbursement approval in Japan for its Optune Lua device, expanding access for non-small cell lung cancer patients. Despite recent positive share price momentum and a perceived undervaluation at $13.42 against a fair value of $25.21, the company faces ongoing losses and concentration risks with its single TTFields platform. Investors are encouraged to assess whether future growth is already priced in or if there is further upside potential.
NovoCure (NASDAQ:NVCR) CFO Sells $85,343.72 in Stock
NovoCure (NASDAQ:NVCR) CFO Christoph Brackmann sold 6,412 shares of the company's stock for a total of $85,343.72 on March 4, reducing his stake by 3.39%. Following the transaction, his direct ownership stands at 182,842 shares, valued at approximately $2.43 million. The company's stock experienced a 6% increase to $14.23, trading above its average volume, and recently reported better-than-expected EPS while analysts maintain a "Hold" rating with an average target price of $26.93.
NovoCure (NASDAQ:NVCR) CEO Sells $74,629.17 in Stock
NovoCure CEO Frank Leonard sold 5,607 shares of company stock for $74,629.17 on March 4th, reducing his stake by 1.12%. Despite beating Q4 EPS estimates, the company remains unprofitable with a negative ROE and net margin. Analysts have a "Hold" rating on NVCR, with a consensus target price of $26.93.
NovoCure (NASDAQ:NVCR) COO Mukund Paravasthu Sells 43,246 Shares
NovoCure's COO, Mukund Paravasthu, sold a total of 48,623 shares in two transactions in early March 2026, significantly reducing his stake in the company. These sales occurred after NovoCure beat EPS estimates in Q4 but remained unprofitable. The stock currently holds an average "Hold" rating from analysts.
Assessing Novocure (NVCR) Valuation After Japan Reimbursement Approval For Optune Lua
Novocure (NVCR) recently received reimbursement approval in Japan for its Optune Lua device, offering a new market for its cancer treatment. Despite recent positive share price returns, long-term performance has declined significantly. The article suggests that while there's a view of NVCR being undervalued with significant upside potential due to future market expansion and revenue growth, investors should consider ongoing losses and the concentration of its technology in a single platform, along with current valuation metrics compared to industry averages and peers.
NovoCure (NVCR) COO offloads 1,963 shares in tax sell-to-cover
NovoCure Ltd COO Paravasthu Mukund sold 1,963 ordinary shares in two open-market transactions on February 27, 2026, and March 2, 2026. These sales were mandated "sell to cover" transactions to meet tax withholding obligations from vested Restricted Stock Units, not discretionary trades. After these transactions, Mukund directly owns 76,343 ordinary shares of NovoCure.
[144] NovoCure Ltd SEC Filing
This article reports on a Form 144 SEC filing by NovoCure Ltd (NVCR), detailing the proposed sale of securities. The filing indicates a neutral impact and sentiment according to Rhea-AI, with securities to be sold through Morgan Stanley Smith Barney LLC. The document provides crucial information about the acquisition of the securities and details of the filer and issuer.
Vanguard Group Inc. Sells 296,555 Shares of NovoCure Limited $NVCR
Vanguard Group Inc. reduced its stake in NovoCure Limited by 2.8%, selling 296,555 shares and retaining ownership of 10,455,841 shares. Despite beating quarterly EPS estimates and showing an 8.2% year-over-year revenue increase, NovoCure remains unprofitable. Analyst sentiment is mixed, with a consensus "Hold" rating and an average price target of $26.93 against a current trading price of around $13.30.
NovoCure Limited $NVCR Shares Bought by Quantbot Technologies LP
Quantbot Technologies LP significantly increased its stake in NovoCure Limited by 163.6% in the third quarter, now holding 195,515 shares valued at $2.53 million. Despite beating EPS estimates and showing an 8.2% year-over-year revenue increase, NovoCure remains unprofitable with a negative net margin. Analysts have a "Hold" consensus rating with a target price of $26.93, although individual price targets vary.
NovoCure (NVCR) CHRO sells 1,441 shares in tax withholding trade
NovoCure Ltd.'s Chief Human Resources Officer, Michal Nath Puri, reported an automatic sale of 1,441 Ordinary Shares on February 27, 2026. The shares were sold at a weighted average price of approximately $13.66 per share to cover tax withholding obligations linked to the vesting of Restricted Stock Units. This was a mandatory "sell to cover" transaction, not a discretionary trade, and Puri now directly holds 162,322 Ordinary Shares.
NovoCure Ltd SEC Filing
This SEC filing ([144] NovoCure Ltd) indicates a proposed sale of 71,887 shares of common stock by NovoCure Ltd, with an aggregate market value of $932,884.79. The securities were acquired on March 3, 2026, as "Performance Shares" from the Issuer and are intended for sale on NASDAQ through Morgan Stanley Smith Barney LLC. The filing also notes recent news and other SEC filings related to NovoCure.
Equity awards and tax share withholding for NovoCure (NVCR) ex-CEO Cordova
NovoCure's former CEO, Ashley Cordova, reported equity award activity, including the vesting of 23,818 performance-based restricted stock units on February 28, 2026. This activity was accompanied by several non-discretionary tax-withholding dispositions on February 27 and March 2, 2026, totaling 21,179 shares at prices of $13.75 and $13.67, to cover tax obligations. These transactions were filed on a Form 4 and are explicitly stated to be tax-withholding events, not open-market sales.
NovoCure (NASDAQ: NVCR) General Counsel receives 17,755-share performance award
NovoCure Ltd's General Counsel, Ben Arye Barak, was granted 17,755 ordinary shares on February 28, 2026, as part of a performance-based restricted stock unit vesting, with a stated price of $0.00 per share. This transaction, detailed in a Form 4 SEC filing, increased Barak's direct holdings to 192,328 ordinary shares and is compensation-related rather than an open-market purchase or sale.
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update
NovoCure (NVCR) shares saw a significant jump following FDA approval of Optune Pax for pancreatic cancer and a positive 2026 revenue guidance update. The approval expands NovoCure's treatment platform beyond glioblastoma, opening new commercial and reimbursement avenues. While this de-risks execution, investors remain cautious about the company's persistent losses and the path to sustained profitability.
NovoCure Ltd. Hits Day Low of $11.80 Amid Price Pressure
NovoCure Ltd. experienced a significant stock decline, reaching an intraday low of $11.80, and has substantially underperformed the S&P 500 over the past one, five, and ten years. Despite holding a strong cash position, the company's profits have decreased, and the stock is trading at a premium valuation with 100% institutional holdings.
NovoCure Ltd wins Japanese reimbursement approval for lung cancer treatment
NovoCure Ltd has received approval from Japan's Ministry of Health, Labour and Welfare for reimbursement of its non-small cell lung cancer treatment. This approval means the treatment will be covered under Japan's National Health Insurance, significantly increasing patient access in the country. The milestone represents a major expansion of NovoCure Ltd's global market presence.
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile
NovoCure has received FDA approval for Optune Pax for locally advanced pancreatic cancer, expanding its Tumor Treating Fields technology beyond glioblastoma. This approval, coupled with a new CEO and clinical team reorganization, marks a significant shift for the company following a period of substantial share price decline. The focus for investors now turns to the rapid uptake of Optune Pax in the new market and the effectiveness of the new leadership in executing commercialization and development plans.
NovoCure (NVCR) Is Up 24.5% After FDA Approval Of Optune Pax And 2026 Guidance Update
NovoCure (NVCR) stock rose 24.5% following FDA approval for Optune Pax for locally advanced pancreatic cancer and an updated 2026 net revenue guidance of US$675 million to US$705 million. This approval signifies a shift towards a broader multi-indication platform, expanding beyond its glioblastoma focus. While the new product diversifies the company's offerings and opens new markets, the article highlights the importance of real-world uptake and reimbursement for Optune Pax and notes that NovoCure still faces challenges with persistent losses.
Novocure (NVCR) Gains Japanese Reimbursement Approval for Optune Lua
Novocure (NVCR) has received reimbursement approval for its Optune Lua device in Japan, allowing coverage under Japan's National Health Insurance. This approval is for adult patients with unresectable advanced or recurrent non-small cell lung cancer who have not responded to platinum-based chemotherapy. Despite this significant milestone, Novocure faces financial challenges including negative operating and net margins, and its Altman Z-Score indicates potential bankruptcy risk.
Japan’s health system to cover wearable lung cancer device Optune Lua
Novocure announced that Japan's Ministry of Health, Labour and Welfare has approved national health insurance reimbursement for its Optune Lua device. This covers adult patients with unresectable advanced/recurrent non-small cell lung cancer (NSCLC) who have progressed after platinum-based chemotherapy. Optune Lua is a wearable device that uses Tumor Treating Fields (TTFields) to target and kill cancer cells.
NovoCure Earnings Call: Growth Builds Amid Profit Strain
NovoCure's recent earnings call revealed a mix of record revenue and increasing patient adoption, particularly in international markets, alongside ongoing profitability issues. Despite a faster-than-expected FDA approval for Optune Pax in pancreatic cancer and a strengthened balance sheet, the company faces pressures from gross margin compression, rising R&D costs, and slower-than-anticipated monetization of new indications due to reimbursement lags. NovoCure provided its first formal 2026 outlook, targeting $675 million to $705 million in net revenue and aiming for adjusted EBITDA between negative $20 million and breakeven.
Novocure Ltd (NASDAQ:NVCR) Reports Mixed Q4 2025 Results, Stock Falls on Revenue Miss
Novocure (NASDAQ:NVCR) reported mixed Q4 2025 financial results, with an 8% year-over-year revenue increase to $174.4 million, which missed analyst estimates, but a better-than-expected net loss per share of $0.22. The company, known for its Tumor Treating Fields (TTFields) therapy, also announced record patient growth, FDA approval for Optune Pax for pancreatic cancer, and provided a 2026 revenue outlook of $675 million to $705 million, which is slightly below analyst consensus, leading to a negative market reaction.
NovoCure’s Pancreatic Cancer Approval And New CEO Shift Risk Reward Profile
NovoCure (NasdaqGS:NVCR) recently received FDA approval for Optune Pax for locally advanced pancreatic cancer and has begun its commercial launch, expanding its Tumor Treating Fields technology. This development, coupled with a new CEO and clinical team reorganization, aims to prepare the company for a broader market presence after a period of significant stock decline. Investors are now focused on the adoption rate of Optune Pax and the new leadership's effectiveness in execution, especially as the company remains loss-making.
